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1. Introduction
Spasticity was defined by Lance as a “velocity-dependent increase in tonic stretch reflexes
(muscle tone) with exaggerated tendon jerks, resulting from hyperexcitability of the stretch
reflex” (Young RR, 1994; Francisco GE, Ivanhoe CB, 1997).
Young further added characteristics of positive and negative symptoms. Positive symptoms
consist of exaggerated cutaneous reflexes, including nociceptive and flexor withdrawal
reflexes, autonomic hyperreflexia, dystonia, and contractures. Negative symptoms include
paresis, lack of dexterity, and fatigability (Young RR, 1994).
Treatment for spasticity was documented as early as the late 19th century, when surgeons
Abbe and Bennet discussed decreasing tone in a spastic limb through sensory rhizotomies.
Later, in 1898, the scientist Sherrington published experiments in which the sensory roots of
spastic cats were severed to relieve spasticity (Abbott R, 1996).
The technique of sensory rhizotomies has been improved on and continues to be used today
as a treatment for patients with spasticity as does neuromuscular blockage, a longstanding
treatment, which has been used for over 30 years (Koman LA, Mooney JF, Smith BP, 1996).
1.1. Cerebral palsy
Cerebral palsy (CP) is a group of permanent disorders of the development of movement and
posture, causing activity limitation, that are attributed to non-progressive disturbances that
occurred in the developing foetal or infant brain. The motor disorders of cerebral palsy are
often accompanied by disturbances of sensation, perception, cognition, communication, and
behavior, by epilepsy, and by secondary musculoskeletal problems (Glinac A, Tahirović H,
Delalić A, 2013).
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The research Frequency of joined disabilities of children with cerebral palsy in Tuzla canton covers a
total sample of 48 examinees, chronological age from 2-19 years, in Tuzla Canton. Research
instrument was a Structural Questionnaire for the parents of children and adolescents with
cerebral palsy. Research data were processed by nonparametric statistics method. Basic
statistical parameters of frequency and percentages were calculated, and tabular presentation
was made. After classification of examinees as per frequency of joined disabilities was done,
work results have shown that speech impairment occurred with 35.4 % of children, visual
impairment 33.3 %, epilepsy 29.3 %, whereas hearing impairment occurred with 2 % of children
(Babajić M, Švraka E, Avdić D, 2013).
Although there are many possible causes of spasticity, this chapter will focus on children with
spasticity, most of whom have diagnoses of cerebral palsy; approximately two thirds of all
cerebral palsy patients suffer from spasticity (Albright AL, 1996).
A patient with spastic cerebral palsy presents with muscle imbalance, stands with bent knees
and legs tightly together, and in severe cases, a scissors-type gait (Frerebeau PH, et al, 1991;
Adams RD, Victor M, Ropper AH, 1997). The antigravity muscles are predominantly affected
with arms in a flexed and pronated position and legs in an extended and adducted position.
When the muscles are at rest they are flaccid to palpation and electromyographically silent.
Spasticity can be associated with cocontraction, clonus and hyperreflexia. Children with
spastic cerebral palsy generally have a typical pattern of muscle weakness, impairment in
selective motor control and sensory impairment (Mikov A, Dimitrijević L, Sekulić S, Demeši-
Drljan Č, Mikov I, Švraka E, Knežević-Pogančev M, 2011).
Many children with more severe spastic CP experience communication problems due to distur‐
bed neuromuscular control of speech mechanism, i. e, dysarthria, that diminish the ability of
the child to speak intelligibly. However, substantial dysarthria are most often seen in children
with severe CP and intellectual disability, while most children with mild and moderate CP
and average cognitive level of functioning have normal or near-normal expressive language
and articulation skills (Bottcher, 2010).
1.2. Etiology and epidemiology
Spasticity may result from either diffuse or localized pathology of the cerebral cortex, brain
stem, or spinal cord. Possible causes of such injuries include traumatic brain injury, stroke,
multiple sclerosis, spinal cord trauma, or disease and anoxic insults. The neurologic localiza‐
tion of the lesion causing spasticity may result in different clinical manifestations. Thus, it is
important to consider whether the spasticity results from cerebral pathology, whether it is
diffuse or localized, or whether it is a result of spinal cord injury.
Diffuse cerebral injury or diseases would include anoxia, toxic, or metabolic encephalopathy,
where as localized cerebral injury would include tumor, abscess, cyst, arteriovenous malfor‐
mations, hemorrhage, or trauma.
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Spinal cord injury or disease may result as an insult to descending pathways by trauma,
inflammatory or demyelinating disease, degenerative disorders, or compression such as is
caused by a tumor or cyst (Albright AL, 1996; Frerebeau PH, et al, 1991; Dimitrijevic MR, 1991).
The annual incidence of spinal cord injuries in the United States is estimated to be 30 to 40 new
cases per million individuals. About 3% to 5% of cases each year occur in children younger
than 15 years of age (Price C, Makintubee S, Herndon W, Istre GR, 1994).
The male-to-female ratio of patients is 4:1 in the general population, but in younger age groups,
the ratio is approximately 1.5:1 (Zidek K, Srinivasan R, 2003).
According to the time of insult, causes of cerebral palsy can be divided to prenatal (from
conception till beginning of delivery), perinatal (started from beginning of labor till end of
neonatal period; first 28 days of life) and postnatal (from 29th day of age until two years of age).
The majority of international studies indicates that the prevalence of cerebral palsy is about
2-2,5 cases per 1000 born, although there are some reports about lower and higher prevalence
rates. Majority of previous research in the world was focused on the prevalence, determination
of the motor abilities, and perinatal etiological factors of the cerebral palsy. Evidences indicated
that 70-80 % of cerebral palsy is caused by the prenatal factors and that the birth asphyxia has
a relatively minor role with the less than 10 % (Švraka E, 2012).
Common causes of cerebral palsy in children that may result in spasticity are prolonged second
stage labor, fetal distress, cystic degeneration of the brain, prematurity, periventricular
encephalomalacia, cortical abnormalities such as porencephaly, or congenital malformations
of gyri such as micropolygyria.
Through the last decades, marked improvement in the level of intensive care at Neonatal
Intensive Care Units (NICU) which was reflected on an increase in the survival of very low
birth-weight (VLBW) and extremely low birth-weight (ELBW) premature newborns. New risk
factors have appeared among infants who previously would have died, and the incidence of
neurodevelopmental impairments in survivors of NICU is higher than in normal birth-weight
newborns. In particular, due to the high risk of interventricular haemorrhage and periven‐
tricular leukomalacia, an increasing prevalence of cerebral palsy has occurred in premature,
low birth-weight newborns and children born with asphyxia (Švraka E, 2012).
Spasticity is present in about two thirds of cerebral palsy patients, and cerebral palsy affects
anywhere from 1.5 to 2.5 per 1000 live births in the United States (Adams RD, Victor M, Ropper
AH, 1997).
The number of spastic patients continues to increase due to an increased survival rate of
premature births. Males and females are equally affected.
1.3. Pathogenesis and pathophysiology
There are many different types of spasticity. Because of this, more than one mechanism may
be responsible for the disturbance in muscle tone and the mechanisms may vary between
patients. The neuropathophysiologic processes involved in spasticity are complex and not
fully understood, but there is a widely accepted hypothesis that spasticity depends on
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hyperexcitability of spinal alpha motor neurons, which is due to the interruption of descending
modulatory influences carried by the corticospinal, vestibulospinal, and reticulospinal tracts
and other possible tracts (Filloux FM, 1996).
Ia afferent fibers provide segmental input from muscle spindles to alpha motor neuron pools.
They synapse on segmental inhibitory interneurons that then inhibit alpha motor neurons
innervating antagonist muscles in the Ia reciprocal inhibition pathway. Ib afferents inhibit
alpha motor neurons by way of the Golgi tendon organs via the Ib inhibitory interneuron in
another pathway known as nonreciprocal inhibition (Young RR, 1994; Filloux FM, 1996).
Increased excitation of these afferents does not seem to be the cause of spasticity. Instead,
evidence supports that reduced reciprocal inhibition of antagonist motor neuron pools by Ia
afferents, decreased presynaptic inhibition of Ia afferents, and decreased nonreciprocal
inhibition by Ib terminals are all possible pathophysiologic mechanisms of spasticity (Young
RR, 1994).
The pathophysiology of traumatic brain injury involves a complex combination of forces that has
been a subject of substantial debate (Drew LB. and Drew WE, 2004).
On occasion, autonomic dysreflexia may occur after an intramuscular injection, although this is
relatively rare (Selcuk B, Inanir M, Kurtaran A, Sulubulut N, Akyuz M, 2004).
In some patients, autonomic dysreflexia may occur even if the level of spinal injury is below
T6 (Blackmer J, 2003; Krassioukov AV, Furlan JC, Fehlings MG, 2003).
1.4. Diagnostic procedure
Examination should begin with the patient in a relaxed, lying position with the head up and
arms resting to the sides because it is easier to determine the extent of spasticity in this position.
The examination should include tonic stretch reflexes by manual passive stretches, elicitation
of tendon jerks and clonus in a relaxed position, and tonic and phasic stretch reflexes carried
out in a sitting position.
The manual passive stretch maneuver is used to assess resistance at different rates. A joint is
passively moved while the muscles corresponding to that joint are lengthened and shortened.
In cases of mild spasticity, the muscles will only resist when stretched at a high rate, whereas
in cases of moderate spasticity, resistance is noticed at a slower rate and the clasp-knife
phenomenon may be exhibited. Movement of the muscle may be difficult to impossible in cases
of severe spasticity (Dimitrijevic MR, 1991).
Tendon jerks are easier to elicit in spastic patients than in patients with normal muscle tone,
and reflex responses can be achieved in muscles without well-defined tendons. Percussion of
the tendon reveals hyperactive tendon jerks, especially for the Achilles, patellar, biceps, and
triceps tendons (Zidar J, Dimitrijevic MR, 1991).
Measurement of resistance to passive stretch, reduction in the tonic vibration reflex, and
reduction of the plantar withdrawal reflex should also be evaluated. Motoneuronal overac‐
tivity should also be evaluated because any input to motoneurons produces excessive and
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prolonged activity that can be observed in the contractions of many limb muscles (Zidar J,
Dimitrijevic MR, 1991).
The amount of function the patient derives from spasticity can be evaluated by having the
patient obtain and maintain standing and seated positions. To determine the degree to which
the hamstring tone is affecting the alignment of the pelvis and knees, have the child sit with
feet straight in front. The patient can sit in a chair to allow the examiner to assess trunk control.
The side sit position exhibits a patient’s ability to maintain control in an asymmetric position
(Abbot R, 1991).
Modified Ashworth Scale (MAS) has been used as a diagnostic test for spasticity. Testing can be
done to establish the presence of any lesion or brain or spinal cord injury. The muscle tone is
graded according to the Modified Ashworth scale (MAS), a scale ranging from 1 to 5, in which
resistance to the passive muscle stretch is measured at various velocities; MAS: 0 = No increase
in muscle tone, 1 = Slight increase in the muscle tone, manifested by catch and release or
minimal resistance at the end of the range of motion, 2 = more marked increase in the muscle
tone through most of the range of motion, but affected parts are easily moved, 3 = considerable
increase in the muscle tone, and passive movements are difficult, 4 = affected parts are rigid
in flexion or extension (Albright AL, 1996).
MRI of the brain can be performed to rule out periventricular leukomalacia.
On EMG, the jerks show greater amplitudes than are normal and are followed by after-
discharge of the motor units that is often slightly longer lasting than normal. The size of tendon
jerks can be measured by either EMG response or by recordings of mechanical events.
H-reflex studies are electrically elicited tendon jerks and are restricted mostly to the soleus and
flexor carpi radialis muscles in normal adults. In cases of upper motor neuron lesions, the H-
reflex may be elicited in muscles where it is not normally seen, such as the intrinsic hand
muscles, tibialis anterior, or peroneal muscles (Zidar J, Dimitrijevic MR, 1991).
A baseline EEG to establish underlying seizure activity can also be done as well as basic lab
studies. Neurophysiological studies, such as the H-reflex study, may be performed in patients
with neurodegenerative disease; an enzymatic assay should also be performed.
Video cameras are often helpful during evaluation as the patient’s movements can be recorded
and compared against movements during and after treatment.
Test Use
Basic lab studies Metabolic derangement
Enzymatic assay Neurodegenerative disease
EEG Underlying seizure activity
NCS Neurodegenerative disease (Leukodystrophies)
MRI of the brain Periventricular leukomalacia
Table 1. Useful Tests for Diagnosis
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1.5. Differential diagnosis
Spasticity can be confused with rigidity when a patient is being evaluated. Stretching can
distinguish rigidity from spasticity. Rigidity will relax through repeated stretching of a muscle,
whereas a spastic muscle will continue to increase in resistance as the velocity of the stretch is
increased (Young RR, 1994; Dimitrijevic MR, 1991).
1.6. Quality of life
In families who have children with CP the “constant attendance” of the disease is present,
through strict consistent long-term care of family and many other factors, such as services,
support and physical aspects of the environment, which all can lead to deterioration of the
patient’s quality of life (Glinac A, Tahirović H, Delalić A, 2013).
The study Family quality of life: adult school children with intellectual disabilities in Bosnia and
Herzegovina, provides initial data for family quality of life in Bosnia and Herzegovina (B&H).
It also provides suggestions for improving quality of life for families that have one or more
members with intellectual disability (ID). The principle measure used was the Family Quality
of Life Survey 2006 – main caregivers of people with intellectual or developmental disabilities. The
sample consisted of the main caregivers in 35 families that have adult children 18 years and
over with ID who attended classes in a specially adapted programme in the Centre for children
with ID, autism and cerebral palsy (n = 16), and in the Vocational Secondary School, B&H (n
= 19). Regarding diagnosis as reported by main caregivers, 15 sons or daughters had ID of
unknown aetiology, eight had cerebral palsy, four had Down syndrome, four had epilepsy
and another three had epilepsy as a co-morbidity, two had autism and two had Prader-Willi
syndrome. One had a dual diagnosis, ID and mental illness. When asked to rate overall family
quality of life, three said ‘excellent’, eight said ‘very good’, 16 said ‘good’, seven said ‘fair’ and
one said ‘poor’. Furthermore, when asked to rate their overall satisfaction with their family
quality of life, two said ‘very satisfied’, 19 said ‘satisfied’ and 13 said ‘neither satisfied nor
dissatisfied’ (Švraka E, Loga S, Brown I, 2011).
Spasticity results in limited functional capacity and increased inactivity. The sequelae of this
inactivity may include decubiti, cardiovascular problems, thrombophlebitis, respiratory
infections, fixed contractures, osteoporosis, bladder and bowel problems, and social isolation.
Ultimately, these consequences of inactivity may lead to a further decrease in strength and
function (Francisco GE, Ivanhoe CB, 1997).
The patient’s quality of life may be compromised as spasticity has negative impacts on mobility,
hygiene, self care, sleeping patterns, self esteem, mood, and sexual function.
It is important to evaluate the advantages and disadvantages that the patient gains from their
spasticity so that treatment strategies and goals can be identified. Disadvantages may include
interference with activities of daily living, inhibition of good sleep, contractures, dislocations,
skin breakdown, bowl and bladder dysfunction, impairment of respiratory function, pain with
stretching, and the masking of the return of voluntary movement. However, patients may rely
on a certain amount of spasticity to function and the advantages they may receive include
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maintaining muscle tone, supporting circulatory function, assisting in activities of daily living,
and preventing the formation of deep vein thrombosis.
2. Case study of two children with CP
2.1. Patient A
Patient A was a 5-year-old African-American boy with a history of developmental delay and
a diagnosis of cerebral palsy of the spastic-diplegic type. He first presented at 18 months with
severe spasticity in both lower extremities. Prior to treatment with botulinum toxin, the patient
walked on tip toes and had hip and knee flexion. There was some scissoring of his legs. On
examination, exaggerated deep tendon reflexes were elicited, as were sustained clonus and
bilateral Babinski sign. MRI of the brain showed findings that may be secondary to previous
hypoxic injury, compatible with cerebral palsy.
Prior treatments included physical therapy, bilateral ankle-foot orthosis, serial casting, and oral
baclofen. This boy with spastic-diplegic cerebral palsy walked on tip toes until treatment with
botulinum toxin injections.
Following botulinum toxin injection, at the age of 18 months, the patient’s gait has improved;
he is flat-footed and presently wears bilateral ankle-foot orthosis. His hygiene and positioning
have also improved and he returns every 6 months to 9 months for reinjection.
Results of the study Use of Botulinum toxin type a in children with Spastic Cerebral Palsy, support
the idea that younger children may receive more benefit from multilevel botulinum toxin type
A injections, intensivephysiotherapy and appropriate orthotic management compared to older
children. Younger children might have been able to maintain the functional gains because the
motor pattern of very young children provides greater scope for better development and
recovery. A younger child has greater potential than older child for increasing the plasticity
of the central nervous system. Botulinum toxin type A injections should always be used as an
adjunctive treatment to physiotherapy, occupational therapy and orthotic management. In
combination with post-injection physiotherapy this treatment could provide long-term
benefits (Mikov A, Dimitrijević L, Sekulić S, Demeši-Drljan Č, Mikov I, Švraka E, Knežević-
Pogančev M, 2011).
2.2. Patient B
Patient B was a 7-year-old African-American boy with a history of cerebral palsy of the spastic-
diplegic type. On primary examination he presented with tightness of both hamstrings and
heel cords with the right more involved than the left. The patient had good toe standing,
especially on the right side and good sitting balance with a kyphotic sacral-type sitting due to
the tight hamstring. He uses a walker to ambulate and walks on tip toes. The EEG was
abnormal, indicating the presence of epileptiform activity from the left central parietal head
region and diffuse background disorganization, which indicates underlying neuronal dys‐
function.
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Treatments before intrathecal baclofen pump implantation included bilateral ankle-foot orthoses,
tendon releases, alcohol block, and botulinum toxin injections. Before treatment with intra‐
thecal baclofen the patient was dependent on a care giver and used a walker to ambulate. With
the intrathecal baclofen pump the patient has gained function, does not use a walker to
ambulate, and performs activities of daily living independently. With the intrathecal baclofen
pump the patient has gained function, does not use a walker to ambulate, and successfully
performs activities of daily living.
3. Spasticity management
Traditional treatments for spasticity include physical therapy, occupational therapy and
rehabilitation treatments which complete a number of crucial tasks and specific goals in the
treatment of patient with CP, this will promote their sensorimotor development, improve their
overall posture and position and enhance their control of movements in all their daily activities:
a lot of physical therapy approaches were based on different theoretical principles though the
main target is the management of abnormal muscle tone and improving the range of motion
through neurodevelopment therapy, conductive education, constraint induced movement
therapy, etc.
There are other modalities including electrical stimulation and cold temperature (Chiara T,
Carlos J Jr, Martin D, Miller R, Nadeau S, 1998; Pease WS, 1998; Scheker LR, Chesher SP,
Ramirez S, 1999; Kinnman J, Andersson T, Andersson G, 2000).
Occupational therapy is a client-centered health profession concerned with promoting health
and well being through occupation. Possible problems in children with cerebral palsy are
motor, sensor, cognitive, intrapersonal, interpersonal, problems of self care, productivity and
leisure.
Occupational therapy, in which the patient is stretched anywhere from once daily to several
times per day, but this has only a limited effect on the patient’s spasticity. Rehabilitation
treatment options include casting, orthotics or splints, strengthening, electrical stimulation,
practice of functional tasks, sensory integration; muscle stretching, and targeted muscle
training (Fetters L, Kluzik J, 1996).
Within the scope of pediatric neurorehabilitation, distinct diseases can produce specific
complications. These complications; however, can also occur in association with many
disorders. For example, spasticity from injury to the upper motor neuron unit can develop in
many neurologic disorders in children. Several of these complications, such as autonomic
dysreflexia, deep vein thrombosis, and heterotropic ossification, can be severe and potentially
life-threatening (Umphred D, Dewane J, Hall-Thompson M, et al, 2001; Dobkins, BH, 2003;
DeLisa JA, Gans BM, Walsh NE, Bockneck WL, Frontera WR, 2004).
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3.1. Oral medications
Oral medications can be used to decrease spasticity; however, many have unwanted side
effects such as drowsiness, sedation, confusion, and fatigue. Benzodiazepines, such as
diazepam, are rarely used because of their strong sedating effects. They result in enhanced
presynaptic inhibition, but because they are presumed to enhance the postsynaptic effects of
GABA, they can only work if the GABA-mediated process functions. Benzodiazepines have a
long half-life and an active metabolite. Benzodiazepine therapy is indicated in spinal cord
injury and multiple sclerosis with possible application in traumatic brain injury, cerebral palsy,
and cerebrovascular accident. Clinical effects include sedation and reduced anxiety, decreased
resistance to passive range of motion, decreased hyperreflexia, and reduction in painful
spasms. Side effects of all benzodiazepines include sedation, weakness, hypotension, gastro‐
intestinal symptoms, memory impairment, incoordination, confusion, depression, and ataxia.
Also, benzodiazepines are controlled substances with the potential for dependency. Diazepam
is the most widely used benzodiazepine for spasticity management. The recommended initial
dose is 2 mg 3 times daily with a maximum dose of 60 mg daily (20 mg 3 times daily). If
nocturnal spasticity is the presenting problem the patient should be started with a single dose
at night.
Like benzodiazepines, baclofen works centrally. Baclofen binds with GABA-B receptors on
brain and spinal membranes, restricting calcium influx into presynaptic nerve terminals,
thereby reducing spasticity [4]. The use of baclofen is indicated when spasticity is of spinal
origin. The clinical effects include decreased resistance to passive range of motion, decrease in
hyperreflexia, and reduction in painful spasms and clonus.
Unlike benzodiazepines and baclofen, dantrolene sodium works peripherally at the level of
the muscle fiber. It has no effect on neuromuscular transmission, but works by acting directly
on the skeletal muscle, hindering the release of calcium from the sarcoplasmic reticulum,
thereby preventing the excitation-contraction coupling mechanism. This affects both intrafusal
and extrafusal fibers by decreasing the force of muscle contraction. However, this mechanism
is not selective for muscles with increased tone, and the resulting generalized muscle weakness
may weaken respiratory muscles. The use of dantrolene sodium is indicated in treating
spasticity secondary to cerebrovascular accident, cerebral palsy, and has possible applications
for traumatic brain injury, spinal cord injury, and multiple sclerosis. Clinical effects of
dantrolene sodium include decreased resistance to passive range of motion, decrease in
hyperreflexia and tone, and reduction in spasms and clonus.
Another group of oral medications used in spasticity management includes clonidine and
tizanidine, which are alpha 2 noradrenergic receptor agonists that release excitatory neuro‐
transmitters and inhibit supraspinal facilitatory pathways (Young RR, 1994; Francisco GE,
Ivanhoe CB, 1997).
Tizanidine is a new oral antispasticity agent that is selective in decreasing tone and spasm
frequency in only spastic muscles, eliminating the unwanted side effect of generalized muscle
weakness. Tizanidine is reported to have reduced symptoms of spasticity in patients with
multiple sclerosis or spinal cord injury and is well tolerated in most patients. It is an imida‐
Management of Spasticity and Cerebral Palsy
http://dx.doi.org/10.5772/58311
11
zoline derivative similar to clonidine but without the cardiovascular effects when appropri‐
ately titrated. Tizanidine results in a direct reduction of excitatory amino acid release from
spinal interneurons and inhibits facilitatory caerulospinal pathways. Its peak effect occurs 1
to 2 hours following administration and its half-life is 2.5 hours. The clinical effects of tizanidine
include reduced muscle tone, spasm frequency, and hyperreflexia. Animal studies with
tizanidine demonstrate antinociceptive activity under specific conditions with increased dose
titration (McCarthy RJ, Kroin JS, Lubenow TR, Penn RD, Ivankovich AD, 1990).
As with other antispasticity medications, the potential side effects of tizanidine are dose related
and may be mitigated by dosage titration. The potential side effects include drowsiness, dry
mouth, and dizziness. Literature suggests that tizanidine may be better tolerated than other
antispasticity agents as measured by the global tolerance rating scale (Lataste X, Emre M, Davis
C, Groves L, 1994).
In placebo-controlled studies, tizanidine has been shown to be effective in multiple sclerosis
and spinal cord injury. It is also useful for spasticity of spinal pathology when weakness is of
concern. Tizanidine may also prove effective in managing spasticity of cerebral origin (Medici
M, Pebet M, Ciblis D, 1989).
Secondary oral and systemic agents include tiagabine, cyproheptadine, clonidine, lamotrigine,
gabapentin and carbidopa-levodopa (Gracies JM, Nance P, Elovic E, et al, 1997).
Multiple medications have been recommended, of which the most recent addition is gaba‐
pentin (Zidek K, Srinivasan R, 2003).
The use of antihypertensive pharmacologic agents in treating spasticity is unclear because
randomized trials have not been performed. Nifedipine has been used in a bit-and-swallow
technique; more recently, captopril also has been found to be of benefit (Esmail Z, Shalansky
KF, Sunderji R, Anton H, Chambers K, Fish W, 2002).
3.2. Chemo-denervation
Chemo-denervation such as using botulinum toxin type A, has proved easier, more effective,
and less painful for patients. First clinically introduced in the United States in the early 1980s,
botulinum toxin is a potent neurotoxin derived from the anaerobic bacteria Clostridium
botulinum, but when used in treatment, no serious systemic toxin effects have been reported
(Francisco GE, Ivanhoe CB, 1997).
The medication is more costly than alcohol or phenol but the cost is offset by less physician
time and the lack of anesthesia. The formation of antibodies has been a concern, but this can
be prevented by allowing 2 months to 3 months between injections. Botulinum toxin works
by acting in the neuromuscular junction, preventing the release of acetylcholine, which results
in functional denervation. It can be given without EMG and anesthesia, does not cause
dysesthesias, and is no more painful than an injection of saline solution. Effects are local and
last 3 months to 4 months, or longer. It is contraindicated during pregnancy, lactation, in
individuals with neuromuscular disorders (such as myasthenia gravis), in patients taking
aminoglycosides, or in those who have a known allergy to the drug. Adverse effects are not
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common and are usually associated with the site of injection, such as bleeding, bruising, and
soreness or redness at the injection site, or diffusion to nearby muscle groups. In patients that
do not respond to botulinum toxin, possible reasons should be considered before labeling the
patient as unresponsive. Reasons could be related to injection technique, improper toxin
storage, or the patient’s individual characteristics. Overall, botulinum toxin has proven
clinically to be effective, safe, and less painful than other invasive therapies (Francisco GE,
Ivanhoe CB, 1997; Keam SJ, Muir VJ, Deeks ED, 2011).
Botulinum toxin is available in serotypes A and B, which have different unit potencies, side-
effect profiles, and dilution schedules. Both have been used in children with cerebral palsy,
although serotype A has been used more extensively. Dosing guidelines have been suggested
for botulinum toxin A for adult and pediatric patients. Adult recommendations are available
for botulinum toxin B, but studies are ongoing for pediatric patients (Tilton AH, 2003; Schwerin
A, Berweck S, Fietzek UM, Heinen F, 2004; Sanger TD, Kukke SN, Sherman-Levine S, 2007).
Some results suggest that botulinum toxin type A can be effective in reducing muscle tone
over a longer period, but not in preventing development of contractures in spastic muscles.
Mechanical and functional alterations can arise from the muscle tissue itself even though the
nervous system is the site of the primary lesion. The gross mechanical changes occur in skeletal
muscle secondary to spasticity and during development of contracture. Muscle stiffness can
change for a variety of structural reasons, only one of which is altered fiber length. There is
currently no evidence in the literature that muscle fiber length is shortened in contracture or
in spastic skeletal muscle. Contracture formation results from inappropriate architectural
adaptation of extremity muscles in response to upper motor neuron lesion (Mikov A, Dimi‐
trijević L, Sekulić S, Demeši-Drljan Č, Mikov I, Švraka E, Knežević-Pogančev M, 2011).
Several studies have reported the successful use of botulinum toxin A for the treatment of
drooling in children with cerebral palsy, using injection into the submandibular or parotid
glands alone or in combination with other agents. In some studies, the beneficial effects have
lasted for up to 4 months without serious side effects or disturbances of oral function (Jongerius
PH, van den Hoogen F, van Limbeek J, Gabreels FJ, van Hulst K, Rotteveel JJ, 2004; Bothwell
JE, Clarke K, Dooley JM, et al, 2002; Suskind DL, Tilton A, 2002).
Other treatments include chemical neurolysis, in which the nerve conduction is impaired
through the use of chemical agents and therapeutic nerve block using phenol or alcohol. The
goals of these treatments are to prevent muscle contractures and improve the patient’s
function. A common side effect is that after the nerve is injected, alcohol levels measure above
the legal limit in children. Other side effects include damage to sensory and motor nerves, pain
at injection site, scarring, and dysesthesias. To ensure the correct site, injection must be made
using an electrical stimulator (Albright AL, 1996; Francisco GE, Ivanhoe CB, 1997).
3.3. Neurosurgical approaches
Another treatment used alleviate spasticity in children with cerebral palsy is rhizotomy. Studies
have shown that performing selective dorsal rhizotomy at a young age can reduce the need
for orthopedic surgery (Chicoine MR, Park TS, Kaufman BA, 1997).
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Goals of rhizotomy are decreased tone, increased mobility, and the facilitation of care for the
patient, however, the reduction in spasticity cannot be predicted and sometimes results in
excessive hypotonia (Im D, McDonald CM, 1997).
The procedure is very meticulous, requiring general anesthesia and a neurophysiologist who
must be present to identify which nerve is to be severed.
Other neurosurgical approaches include peripheral neurectomy, myelotomy, and dorsal column
electrical stimulation.
It has been established that oral baclofen does not cross the blood-brain barrier effectively and
that higher doses of the medication result in serious side effects (Francisco GE, Ivanhoe CB,
1997).
Intrathecal baclofen results in a greater decrease in spasticity by allowing higher concentra‐
tions of baclofen in the cerebrospinal fluid at about 1% the daily oral dosage (Im D, McDonald
CM, 1997).
To be considered for intrathecal baclofen pump placement, the patient must have severe lower
limb spasticity that does not respond to other less-invasive treatments. The patient must first
be given a trial of 50 µg baclofen through a lumbar puncture or spinal catheter. If unresponsive,
75 µg can be tried after 24 hours and a third trial of 100 µg can be tried 24 hours after that, after
which if the patient is still unresponsive he or she must be excluded from the treatment
(Francisco GE, Ivanhoe CB, 1997).
Implantation lasts 1 to 2 hours and the pump is easy to refill subcutaneously. It is programmed
by a computer-controlled radiotelemetry programmer that is linked to the pump’s internal
computer and that selects the rate and pattern of baclofen administration. Complications to
intrathecal baclofen include hypersensitivity to baclofen, intolerance to the side effects of
baclofen including drug tolerance, cerebrospinal fluid leakage, pump pocket seroma, hema‐
toma, infection, and soft tissue erosion. The objective of intrathecal baclofen is to individualize
the patient’s dose and infusion so that the lowest dose that yields the greatest response can be
achieved (Young RR, 1994; Francisco GE, Ivanhoe CB, 1997).
In comparison, intrathecal baclofen has less complications and side effects than other treat‐
ments and more generalized results in both cerebral and spinal spasticity, making intrathecal
baclofen the most effective current tool for the treatment of spasticity in non-ambulant
individuals. A recent systematic review showed that there was no evidence to support the
clinical use of intrathecal baclofen in ambulant individuals with hypertonicity without further
rigorous longitudinal studies (Pin TW, McCartney L, Lewis J, Waugh MC, 2011).
As a precaution, families are prescribed diazepam or diazepam rectal as well as oral baclofen
to have at home. If there is evidence of withdrawal, one of these medications is administered,
and the patient is instructed to go immediately to the emergency department. Although
aggressive use of benzodiazepines and oral baclofen may be helpful, recognition and return
to appropriate intrathecal baclofen dosage is essential for rapid recovery (Alden TD, Lytle RA,
Park TS, Notzel MJ, Ojemann JG, 2002).
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3.4. Orthopedic procedures
Orthopedic procedures are the most frequently performed operations for spasticity. The targets
of these operations are muscles, tendons, or bones. Muscles may be denervated and tendons
and muscles may be released, lengthened, or transferred. The goals of surgery may include
reducing spasticity, increasing range of motion, improving access for hygiene, improving the
ability to tolerate braces, or reducing pain. Orthopedic problems that may result from a spastic
limb include cubital or carpal tunnel syndrome, spontaneous fracture, dislocation of the hip
or knee, and heterotopic ossification.
The most common orthopedic procedure for the treatment of spasticity is a contracture release.
In this procedure, the tendon of a muscle that has a contracture is partially or completely cut.
The joint is then positioned at a more normal angle, and a cast is applied. Regrowth of the
tendon to a new length occurs over several weeks. Serial casting may be used to gradually
extend the joint. Following cast removal, physical therapy is used to strengthen the muscles
and improve range of motion.
Spastic muscles in the shoulder, elbow, forearm, hands, and legs may all be treated with tendon
or muscle lengthening. Spasticity in the shoulder muscles may cause abduction or adduction
and internal rotation of the shoulder. Abduction results in difficulties with balance, which then
affects walking and transferring, and adduction causes problems when reaching for an object
or with hygiene and personal care. An operation known as a slide procedure may be used to
lengthen the supraspinatus muscle in an abducted spastic shoulder. With adducted shoulders,
the surgeon can perform a release of all 4 muscles that typically cause this deformity.
In an operation known as a tendon transfer, the orthopedic surgeon moves a tendon from the
spot at which it attaches to the spastic muscle. With the tendon transferred to a different site,
the muscle can no longer pull the joint into a deformed position. In some situations, the transfer
allows improved function. In others, the joint retains passive but not active function. Ankle-
balancing procedures are among the most effective interventions.
The goal of surgical-orthopedic treatment which is basically symptomatic improve or facilitate
the movement to solve the functional or fixed contractures preventing further rehabilitation,
to solve the deformation that reduces or prevents movement, sitting, causing pain as in the
cases of hip luxation, or threaten respiration as in cases of severe scoliosis. Subluxation and
dislocations of the hip in children with CP are most common in children and adolescents who
do not walk. We must bear in mind the saying that every child and adolescent with CP has a
hip disorder until proven otherwise. The occurrence of dislocation of the hips makes furniture,
hygiene and often causes pain. Requires regular radiological controls hips once or twice a year
in the course of growth, to hip dislocation discovered at an early stage. Subluxation and
luxation of the hips treated surgically. The decision about surgery should bring those involved
in the treatment of patients, carefully weighing hopper performs coarse benefits and harms of
surgery. Surgery is necessary to balance the muscle forces around the hip and normalize
abnormal anatomic relationships (Đapić T, Šmigovec I, Kovač-Đapić N, Polovina S, 2012).
Osteotomy and arthrodesis involves operations on the bones and are usually accompanied by
operations to lengthen or split tendons to allow for fuller correction of the joint deformity.
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Osteotomy can be used to correct a deformity that cannot be fixed with other procedures. In
an osteotomy, a small wedge is removed from a bone to allow it to be repositioned or reshaped.
A cast is applied while the bone heals in a more natural position. Osteotomy procedures are
most commonly used to correct hip displacements and foot deformities. Arthrodesis is a fusing
together of bones that normally move independently. This fusion limits the ability of a spastic
muscle to pull the joint into an abnormal position. Arthrodesis procedures are performed most
often on the bones in the ankle and foot. In triple arthrodesis, the 3 joints of the foot are exposed,
the cartilage is removed, and screws are inserted into the bones, fixing the joints into position.
With a short walking cast in place for 6 weeks or until the bones have fully healed, the patient
may bear weight immediately after the operation (http://wemove.org/spa/spa_oss.html 2007).
The risks of developing a structural spinal deformity ranges from 24% to 36% for scoliosis and
is 50% for lordosis for an average of 4 to 11 years after selective dorsal rhizotomy ( Turi M,
Kalen V, 2000; Johnson M, Goldstein L, Thomas SS, Piatt J, Aiona M, Sussman M, 2004).
Other principals include single event, multilevel surgery; surgery is delayed as long as possible
(more than 6 years). Spasticity management is used as an adjunct to surgical intervention (Boyd
R, Graham J, Nattras G, Graham K, 1999).
3.5. New treatments in spasticity management
Acupuncture and homeopathic approaches (Guo Z, Zhou M, Chen X, Wang R, 1997), herbs
and hyperbaric oxygen [41-45], constraint induced training [46, 47], the Adeli suit [48],
conductive education, craniosacral, and manipulation and patterning.
Context therapy is a new intervention approach that focuses on changing the task and the
environment rather than children’s impairments. It can be a viable treatment to achieve parent-
identified functional goals for children with cerebral palsy (Darrah J, Law MC, Pollock N, et
al, 2011).
A summary of management in spasticity is provided in Table 2.
Therapeutic intervention Mechanisms Major points
Nonpharmacologic treatments
Physical therapy
Occupational therapy
Neurodevelopmental therapy (NDT)
Constraint-induced movement therapy (CIMT)
Neurophysiologically based therapy/ Vojta
Manual medicine
Training of the muscular strength
Treadmill therapy
Conductive education
Hand-arm bimanual intensive therapy (HABIT)
Sensory integration therapy/Ayres
Different techniques are tailored depending on
the individual goals
Training of both manual and fine motor skills of
the paretic side through activity limitation of the
healthy side
Reflex locomotion to encourage motor
development through repetitive triggering reflex
creeping and reflex turning
Encouraging motor learning through active and
passive mobilization, soft tissue release and
manipulations
Encouraging locomotion and posture through
specific training of certain muscle groups
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Therapeutic intervention Mechanisms Major points
Gait training through walking on treadmill, with
body weight support
Systematic, intensive training of small learning
steps in the motor, linguistic and cognitive
domains
Motivation for bimanual activity of the paretic
and nonparetic side with specified tasks
Everyday tasks training for coordination and
sensory information enhancement
Splints, strengthening, electrical stimulation,
practice of functional tasks, muscle stretching,
and targeted muscle training
Mainstays and cornerstones in spasticity
management; complications, such as autonomic
dysreflexia, deep vein thrombosis, and
heterotropic ossification, can be severe and
potentially life-threatening
Casting and orthosis Extend joint range diminished by hypertonicity;
reduce an abnormal pattern by positioning
Temporary effect
Selective posterior rhizotomy Balancing spinal cord-mediated facilitatory and
inhibitory control
Permanent effect; sometimes results in excessive
hypotonia
Orthopedic surgery Corrects deformity induced by muscle
overactivity involving muscles, tendons, or bones
In moderate to severe spasticity, permanent
effect
Pharmacological treatments, oral medications
Benzodiazepine Increases the affinity of GABA for GABA-A
receptors; inhibitory effect at both the spinal
cord and supraspinal levels
Short-term treatment; strong sedating effects
Dantrolene sodium Inhibits release of calcium from sarcoplasmic
reticulum in muscle; works peripherally at the
muscle fibers
Serious side effects; hepatotoxicity in 1%
patients, respiratory muscle weakness
Baclofen GABA agonist; binds at the GABA-B receptor;
restricts calcium influx into presynaptic nerve
terminals in the spinal cord
Rapidly absorbed after oral administration; levels
in the CSF are low because of low lipid solubility
Tizanidine Centrally acting alpha-2 noradrenergic agonist;
inhibits release of excitatory neurotransmitters in
the spinal cord and supraspinally
Drowsiness, dry mouth, and dizziness; monitor
liver function
Pharmacological treatments, chemodenervation
Alcohol/Phenol block Nonselective proteolytic agents; selective
denervation when injecting into motor nerves or
muscles
Damage to sensory and motor nerves, painful
dysesthesias
Botulinum toxin injection High affinity and specificity to the presynaptic
membranes of cholinergic motor neurons
Recommended as effective treatment; no
sensory disturbance
Pharmacological treatments, other
Intrathecal baclofen pump Using a programmable implanted pump,
baclofen can be delivered intrathecally
Severe, generalized spasticity; less complications
and side effects
Table 2. Management in Spasticity
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Pregnancy
The patient with spasticity may expect to have a difficult pregnancy and delivery as well as
difficulty managing and caring for an infant.
Anesthesia
Not applicable.
4. Conclusion
To prevent cerebral palsy in infants and, thus, the resulting spasticity, it is important that
mothers receive prenatal care during pregnancy, that measures are taken to avoid premature
labor, and that special consideration is given to pregnancies involving multiple gestations.
Early detection and treatment of neurodegenerative diseases may prevent the development of
spasticity as well as detect the underlying diseases that could result in brain injury. If children
have conditions that make them susceptible to brain or spinal cord injury or both, safety
measures should be taken (i.e., helmets for patients who have frequent seizures).
The goals of and benefits to the patient are important when considering the path of treatment.
In some cases, function will not return, but treatment can result in pain reduction and allow
easier management of patient care. Common goals are to decrease pain, prevent or decrease
contractures, improve ambulation, facilitate activities of daily living, facilitate rehabilitation
participation, save caregiver’s time, improve the ease of care, and increase safety. Appropriate
management choices are based on therapeutic objectives. Physical and occupational therapists
can play a key role in identifying these objectives. Treatments with the fewest side effects are
usually given priority. Both the patient’s and the caregiver’s goals must be considered.
Rehabilitation multidisciplinary team could be good connection with Management. There are
different approaches in rehabilitation treatment of persons with cerebral palsy, especially
children and adolescents. The treatment of children with spastic cerebral palsy is a combination
of intensive sensorimotor stimuli, physical therapy, occupational therapy, Vojta therapy,
orthopedic procedures and/or botulinum toxin applications. It is child/family-centered
management.
The ICF can guide management but does not give sufficient detail of the “hows and whys of
the child activities to enable a specific treatment plan.
5. Summary
Spasticity may result from either diffuse or localized pathology of the cerebral cortex, brain
stem, or spinal cord. Possible causes of such injuries include traumatic brain injury, stroke,
multiple sclerosis, spinal cord trauma, or disease and anoxic insults. The neurologic localiza‐
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tion of the lesion causing spasticity may result in different clinical manifestations. Thus, it is
important to consider whether the spasticity results from cerebral pathology, whether it is
diffuse or localized, or whether it is a result of spinal cord injury.
Cerebral palsy (CP) is a group of permanent disorders of the development of movement and
posture, causing activity limitation, that are attributed to non-progressive disturbances that
occurred in the developing foetal or infant brain. The motor disorders of cerebral palsy are
often accompanied by disturbances of sensation, perception, cognition, communication, and
behavior, by epilepsy, and by secondary musculoskeletal problems
Spasticity can be associated with cocontraction, clonus and hyperreflexia. Children with
spastic cerebral palsy generally have a typical pattern of muscle weakness, impairment in
selective motor control and sensory impairment.
It is important to evaluate the advantages and disadvantages that the patient gains from their
spasticity so that treatment strategies and goals can be identified. Disadvantages may include
interference with activities of daily living, inhibition of good sleep, contractures, dislocations,
skin breakdown, bowl and bladder dysfunction, impairment of respiratory function, pain with
stretching, and the masking of the return of voluntary movement.
There are many different types of spasticity. Because of this, more than one mechanism may
be responsible for the disturbance in muscle tone and the mechanisms may vary between
patients. The neuropathophysiologic processes involved in spasticity are complex and not
fully understood, but there is a widely accepted hypothesis that spasticity depends on
hyperexcitability of spinal alpha motor neurons, which is due to the interruption of descending
modulatory influences carried by the corticospinal, vestibulospinal, and reticulospinal tracts
and other possible tracts.
Traditional treatments for spasticity include physical therapy, occupational therapy and
rehabilitation treatments which complete a number of crucial tasks and specific goals in the
treatment of patient with CP, this will promote their sensorimotor development, improve their
overall posture and position and enhance their control of movements in all their daily activities:
a lot of physical therapy approaches were based on different theoretical principles though the
main target is the management of abnormal muscle tone and improving the range of motion
through neurodevelopment therapy, conductive education, constraint induced movement
therapy, etc.
Oral medications can be used to decrease spasticity; however, many have unwanted side
effects such as drowsiness, sedation, confusion, and fatigue. Benzodiazepines, such as
diazepam, are rarely used because of their strong sedating effects. They result in enhanced
presynaptic inhibition, but because they are presumed to enhance the postsynaptic effects of
GABA, they can only work if the GABA-mediated process functions.
Chemo-denervation such as using botulinum toxin type A, has proved easier, more effective,
and less painful for patients. First clinically introduced in the United States in the early 1980s,
botulinum toxin is a potent neurotoxin derived from the anaerobic bacteria Clostridium
botulinum, but when used in treatment, no serious systemic toxin effects have been reported.
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Another treatment used alleviate spasticity in children with cerebral palsy is rhizotomy. Studies
have shown that performing selective dorsal rhizotomy at a young age can reduce the need
for orthopedic surgery. Goals of rhizotomy are decreased tone, increased mobility, and the
facilitation of care for the patient, however, the reduction in spasticity cannot be predicted and
sometimes results in excessive hypotonia.
Other neurosurgical approaches include peripheral neurectomy, myelotomy, and dorsal column
electrical stimulation.
Orthopedic procedures are the most frequently performed operations for spasticity. The targets
of these operations are muscles, tendons, or bones. Muscles may be denervated and tendons
and muscles may be released, lengthened, or transferred. The goals of surgery may include
reducing spasticity, increasing range of motion, improving access for hygiene, improving the
ability to tolerate braces, or reducing pain. Orthopedic problems that may result from a spastic
limb include cubital or carpal tunnel syndrome, spontaneous fracture, dislocation of the hip
or knee, and heterotopic ossification.
Abbreviations
EEG: electroencephalogram
EMG: electromyography
MRI: Magnetic Resonance Imaging
ICD codes
ICD-9:
Abnormal involuntary movements: 781.0
ICD-10:
Other and unspecified abnormal involuntary movements: R25.8
Associated disorders
Adrenoleukodystrophy
Anoxia
Cerebral palsy
Multiple sclerosis
Neurodegenerative disease
Spinal cord injury
Stroke
Traumatic brain injury
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Major keyword descriptors
bent knees
gait disturbances
muscle imbalance
poor hygiene
poor positioning
scissors-type gait
stretch reflexes
tendon jerks
Minor keyword descriptors
bladder problems
bowel problems
cardiovascular problems
fixed contractures
osteoporosis
pain
respiratory infections
thrombophlebitis
Glossary
Adrenoleukodystrophy: demyelination of nerve cells in the brain and progressive dysfunction
of the adrenal gland.
Anoxia: diminished supply of oxygen to an organ's tissues.
Cerebral palsy: Nonprogressive disorder or movement and posture that can occur anywhere
from 0 to 5 years of age, caused by a brain lesion.
Clasp-knife phenomenon: characterized by a free interval of movement of the limb, followed
by a sudden stop and increase in muscle resistance which melts away as the passive stretching
of the limb continues.
Multiple Sclerosis: plaques form from inflammation of the white matter of the central nervous
system, causing destruction of the myelin sheath, resulting in diminished or lost function.
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Spasticity
Related topics
Acupuncture
Autosomal dominant inherited ataxias
Baclofen
Cerebral palsy
Childhood ataxia with central nervous system hypomyelination
Childhood movement disorders
Neurodegeneration with brain iron accumulation
Hyperargininemia
Hyperbaric oxygenation for the treatment of stroke
Machado-Joseph disease
Multiple sclerosis
Nonautosomal dominant inherited ataxias
Sjogren-Larsson syndrome
Differential diagnosis
Rigidity
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